Benzinga | Jul 29, 2021 07:25AM EDT

Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

- Results Showed Substantial Reductions in Plasma Oxalate Relative to Baseline in PH1 Patients with Severe Renal Impairment, Including Those on Dialysis, and an Encouraging Safety and Tolerability Profile -

- Alnylam Intends to File Supplemental Regulatory Applications with the U.S. Food and Drug Administration and the European Medicines Agency Based on ILLUMINATE-C Results in Late 2021 -